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Abstract The discovery of a (pro)renin receptor ((P)RR) in
2002 provided a long-sought explanation for tissue renin–
angiotensin system (RAS) activity and a function for circu-
lating prorenin, the inactive precursor of renin, in end-organ
damage. Binding of renin and prorenin (referred to as
(pro)renin) to the (P)RR increases angiotensin I formation
and induces intracellular signalling, resulting in the produc-
tion of profibrotic factors. However, the (pro)renin concen-
trations required for intracellular signalling in vitro are
several orders of magnitude above (patho)physiological
plasma levels. Moreover, the phenotype of prorenin-
overexpressing animals could be completely attributed to
angiotensin generation, possibly even without the need for a
receptor. The efficacy of the only available putative
(pro)renin receptor blocker handle region peptide remains
doubtful, leading to inconclusive results. The fact that, in
contrast to other RAS components, (P)RR knock-outs, even
tissue-specific, are lethal, points to an important, (pro)renin-
independent, function of the (P)RR. Indeed, recent research
has highlighted ancillary functions of the (P)RR as an es-
sential accessory protein of the vacuolar-type H+-ATPase
(V-ATPase), and in this role, it acts as an intermediate in
Wnt signalling independent of (pro)renin. In conclusion,
(pro)renin-dependent signalling is unlikely in non-
(pro)renin synthesizing organs, and the (P)RR role in
V-ATPase integrity and Wnt signalling may explain some,
if not all of the phenotypes previously associated with
(pro)renin-(P)RR interaction.
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Introduction
The renin–angiotensin system (RAS) is a hormonal system
that regulates blood pressure by influencing vasomotor tone
and salt and fluid retention. The central regulator in this
cascade is renin, which catalyzes the rate-limiting step in the
formation of angiotensin (Ang) II, the main effector peptide
of the system. Surprisingly, the inactive precursor of renin,
called prorenin, also circulates in blood, at concentrations
that are ten times higher, and in diabetes and pregnancy
even up to 100 times higher. Interestingly, the elevated
plasma prorenin levels correlate with, and even precede,
the microvascular complications of diabetes, although renin
levels remain in the low–normal range [25, 65]. As these
patients respond well to RAS blockade, it seems likely that
prorenin may somehow contribute to Ang II generation at
tissue sites. However, since the kidney is the only known
site where prorenin-to-renin conversion occurs [60], a long-
standing question is how prorenin might display activity
extrarenally. This appeared to be solved in 2002 with the
discovery of a receptor that could bind and activate prorenin
[76]. This receptor also binds renin and is therefore now
known as the (pro)renin receptor ((P)RR). Following its
discovery, intense research started into its function, which
had some initial success stories, but is recently moving more
and more to prorenin-independent functions. Now, after a
decade of (P)RR research, it is time to make up the score for
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this receptor: Does it deserve its name, and is it still a
potential drug target in cardiovascular disease?
The search for a receptor
Renin is a member of the family of aspartic proteases. These
proteases have two highly conserved aspartic residues in the
active cleft, which work optimally at acidic pH. In this aspect,
renin is an exception, as it cleaves its substrate angiotensinogen
at neutral pH in blood plasma. Renin is produced in juxtaglo-
merular (JG) cells as prorenin, which contains a 43-amino-acid
prosegment that covers the active cleft. The prosegment inac-
tivates the protease and thereby prevents intracellular proteol-
ysis, but it is also thought to be important for folding, stability,
and intracellular sorting of proteases [51]. The prosegment is
removed in lysosome-like structures that subsequently store
renin in dense vesicles [91]. Renin is released from JG cells in
a regulated manner, in response to stimuli like hypotension and
low Na+. Remarkably, the inactive prorenin is also secreted
directly into the bloodstream. This occurs in a constitutive
manner, and prorenin is not stored.
After a bilateral nephrectomy, renin rapidly disappears
from plasma [56]. Prorenin levels also rapidly decline, but
then stabilize due to prorenin synthesis at extrarenal sites,
like the adrenal gland, the testes, the ovaries, placenta, and
the eyes [55]. Recent studies suggest that the collecting duct
in the kidney is an alternative source of prorenin [82],
possibly contributing to the elevated prorenin levels in dia-
betics [49]. Interestingly, although aortic (and cardiac) renin
also disappeared post-nephrectomy, their disappearance oc-
curred much more slowly than that of plasma renin [23, 98].
This suggests that there are binding places that can retain
renin. Such binding places are in agreement with the fact
that the majority of Ang I formation occurs at tissue sites, e.
g., in the vessel wall. The first such receptor that was
identified was the mannose-6-phosphate receptor, which is
identical to the insulin-like growth factor II (IGFII) receptor
and hence is called M6P/IGFII receptor [53]. M6P/IGFII
receptors are present on neonatal cardiac myocytes and
fibroblasts [85], as well as on human endothelial cells
[100] and vascular smooth muscle cells [4]. This receptor
binds phosphomannosylated proteins like renin and prore-
nin with high affinity, and both are internalized rapidly.
Although prorenin was converted to renin intracellularly
following internalization, there is no evidence that this
resulted in either intracellular or extracellular Ang I gener-
ation [85, 100]. In fact, the prorenin-to-renin conversion was
found to be part of a slow intracellular degradation process,
and the M6P/IGFII receptor is therefore now thought to be a
clearance receptor for renin and prorenin [22].
Nguyen and co-workers identified a second receptor in
2002, called the (P)RR, that binds both renin and prorenin
without internalization [76]. The (P)RR induces a fivefold
increase in the activity of bound renin by increasing the
affinity of renin for the oxidized form of its substrate angio-
tensinogen [109]. Binding of prorenin to the (P)RR enables
prorenin to undergo a conformational change that allows it
to gain complete enzymatic activity without proteolytical
removal of the prosegment [4, 5, 72, 76]. Binding possibly
involves a region in the prosegment, and on this basis, an
antagonist (the so-called handle region peptide (HRP)) has
been developed [40, 95].
The many faces of the (pro)renin receptor
The (P)RR is a 350-amino-acid, ubiquitously expressed
transmembrane protein that binds (pro)renin to a large N-
terminal extracellular domain (Fig. 1) [76]. The (pro)renin
binding domain is only conserved in vertebrates, which
probably means that this function of the (P)RR was acquired
during vertebrate evolution [30]. Both prorenin and renin
can bind to purified (P)RR with affinities in the nanomolar
range [4, 72, 76]. However, binding studies in rat vascular
smooth muscle cells that overexpress the human (P)RR have
shown that prorenin binds with higher affinity, suggesting
that prorenin might be the endogenous ligand for the (P)RR
[4]. The (pro)renin-binding domain is followed by a carboxy-
terminal half that is comprised of the rest of the extracel-
lular domain, a single transmembrane domain, and a short
intracellular tail that can form dimers [107]. The carbox-
yterminal part is conserved among all metazoans [30]. It
was previously purified from chromaffin granules as an
8.9-kD accessory protein (M8-9) of the vacuolar-type H+-
ATPase (V-ATPase) and designated ATP6AP2 (ATPase,
H+-transporting, lysosomal accessory protein 2) [64]. This
would imply that the (P)RR can be proteolytically pro-
cessed. Indeed, Cousin et al. [18] found a 28-kD soluble
form of the (P)RR, designated s(P)RR, in the conditioned
medium of several cell types [18]. This form was, howev-
er, absent in the medium of LoVo cells, which are devoid
of the serine protease furin. In addition, the formation of
the s(P)RR was also absent from the medium of CHO cells
after furin inhibition, and recombinant furin could directly
cleave the (P)RR in vitro [18]. Furthermore, a putative
furin cleavage site is predicted around the expected posi-
tion in the (P)RR amino acid sequence (Fig. 1), all sug-
gesting that furin is the protease responsible for the
generation of s(P)RR. This, however, was recently chal-
lenged by Yoshikawa et al. [105], who did find s(P)RR in
the medium of LoVo cells and in the medium of vascular
smooth muscle cells (VSMCs) after furin inhibition. In-
stead, these authors identified the metalloprotease AD-
AM19 as a (P)RR-cleaving protease [105]. s(P)RR
secreted by human umbilical vein endothelial cells
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(HUVECs) and VSMCs appears functional, as it can bind
and activate prorenin [7, 105]. Using immobilized renin,
Cousin et al. precipitated and immunodetected s(P)RR
from human plasma [18]. However, others could only
detect s(P)RR in human urine but not plasma [43]. s(P)
RR was also found in the urine of Ang II infused rats [32].
Whether there is a physiological function for s(P)RR in
angiotensin-generation or signalling is as yet unclear, al-
though some have speculated that s(P)RR itself may act as
a ligand for another, yet unknown, receptor [3].
The (P)RR as a V-ATPase-associated protein
Recent work has indicated the importance of the association
between the (P)RR and V-ATPase for development and cell
survival, independent from (pro)renin. V-ATPases are multi-
subunit proteins that consist of a V0 proton-translocation
domain, a V1 pump domain, and two associated proteins,
Ac45 and the (P)RR. V-ATPases are found in virtually all
cell types, mostly on the membranes of intracellular com-
partments, and are important for among others vesicle traf-
ficking, protein degradation, and coupled transport [99]. In
some cell types, V-ATPases are also abundantly present at
the plasma membrane, for example, in intercalated cells of
the collecting duct, where they regulate systemic acid–base
homeostasis [103] and in osteoclasts, where they are in-
volved in bone resorption [61]. The (P)RR was shown to
colocalize with the V-ATPase at the lumen of intercalated
cells and at the Z-disc and dyad in cardiomyocytes [16].
Insertional mutagenesis of the (P)RR gene in zebrafish and
injection of morpholino RNAs against the (P)RR into
cleavage-staged Xenopus embryos give very similar devel-
opmental phenotypes, with larvae and tadpoles that have
smaller heads and defects in eye and melanocyte pigmenta-
tion [2, 19], similar to the phenotypes found for V-ATPase
subunits mutants [2, 19, 77]. Because (P)RR knock-out mice
are lethal at a very early developmental stage [93], the focus
to unravel the (patho)physiological role of the (P)RR has
shifted to the generation of tissue-specific knockouts. These
studies have indicated an essential role for the (P)RR in V-
ATPase integrity. Cardiomyocyte-specific ablation of the
(P)RR results in a lethal phenotype, with mice dying within
3 weeks of heart failure [52]. Similarly, podocyte-specific
(P)RR knock-out mice are born at Mendelian rates, but,
early in life, develop nephritic syndrome, with severe pro-
teinuria and albuminuria due to progressive glomerular scle-
rosis, and die within 2–4 weeks of renal failure [68, 79, 84].
The podocytes of these mice show massive foot-process
effacements accompanied by alterations in the actin cyto-
skeleton, whereas the slit diaphragm proteins, nephrin and
podocin, have reduced expression and are redistributed to
the cytosol [79, 84]. Both (P)RR depleted cardiomyocytes
and podocytes are highly vacuolarized and show impaired
autophagic degradation (Fig. 2). The autophagy defect is
due to deacidification of intracellular vesicles, which is
caused by the selective downregulation of V0-subunits [52,
79]. These findings show the importance of the (P)RR for V-
ATPase assembly, stability, and function, and suggest that
more than an accessory protein, the (P)RR is an essential V-
ATPase subunit.
The (pro)renin receptor as a signalling receptor
Apart from prorenin activation, the (P)RR can also act as a
signalling receptor for (pro)renin, independent from the
formation of Ang I (Fig. 2). Binding of (pro)renin to the
(P)RR activates the mitogen-activated protein kinase
(MAPK) extracellular signal-regulated kinase 1/2 (Erk1/2)
in several cell types, including mesangial cells [37, 76],
collecting duct cells [1], VSMCs [6, 31, 62], monocytes
[30], and neurons [17]. Activation of Erk1/2 increases cell
proliferation and stimulates production of transforming
growth factor-β1 (TGF-β1), resulting in the upregulation
of profibrotic factors, such as the plasminogen-activated
inhibitor-1 (PAI-1), fibronectin, and collagen [37, 38, 106].
Increased expression of the NADPH oxidase isoform 4 [14]
may be involved. Prorenin binding also induces the activa-
tion of the serine/threonine kinase Akt in VSMCs [62] and
of the p38 MAPK–heat-shock protein 27 cascade in cardi-
omyocytes [86]. The latter cascade regulates actin cytoskel-
eton dynamics. How does the (P)RR signal towards
downstream effectors? The (P)RR shares no homology with
known signalling receptors, and amino acid sequence of the
short intracellular tail predict no protein–protein interaction
domains, however, possible candidates have been identified.
Using a yeast two-hybrid system, Schefe et al. showed that
the promyelocytic leukemia zinc finger (PLZF) can act as a
(P)RR binding protein (Fig. 2) [89, 90]. Prorenin binding
induces the translocation of PLZF to the nucleus, where it
activates the expression of the p85-subunit of phosphoinosi-
tide 3-kinase, resulting in enhanced protein synthesis, cell
proliferation, and decreased apoptosis. Whether PLZF is
also involved in the activation of other signalling molecules
such as Erk1/2 is as yet unknown but seems unlikely as it is
a transcriptional regulator rather than a signalling protein.
COOH
*
TM
intracellularextracellular
s(P)RR M8-9
SPNH2
Fig. 1 Predicted domain structure and proteolytic fragments of the
(P)RR. A putative furin cleavage site is indicated by an asterisk.
Abbreviations: SP, signal peptide; TM, transmembrane domain
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Erk1/2 can be activated by some G-protein-coupled recep-
tors, for example, the angiotensin II type 1 receptor (AT1),
through transactivation of growth factor receptors [27]. This
may also be true for the (P)RR, as in VSMCs, prorenin-
induced transactivation of the epidermal growth factor re-
ceptor (EGFR) is required for Erk1/2 and Akt phosphoryla-
tion [62]. Erk1/2 activation is also linked to V-ATPase
activity, as prorenin-induced Erk1/2 phosphorylation in
Madin Darby Canine Kidney (MDCK) cells, a model for
collecting duct cells, is inhibited by the V-ATPase inhibitor
bafilomycin A1 [1]. Studies in our lab have shown that
prorenin directly stimulates plasma membrane-associated
V-ATPase activity in MDCK cells (Fig. 2) [63], indicating
that the V-ATPase may increase intracellular pH (pHi) above
a permissive level required for Erk1/2 activation, compara-
ble to Ang II activation of Erk1/2 in rat aorta smooth muscle
cells [71]. How the (P)RR activates the V-ATPase is as yet
unclear. This could involve increased cycling of V-ATPase-
containing vesicles to the membrane by changes in actin
cytoskeletal dynamics [20, 86] or, since it directly binds to
V-ATPase [19], a conformational change in the complex. In
summary, (pro)renin induces multiple signalling pathways
via the (P)RR in cell models. Is this also reflected in vivo?
Lessons from humans
A unique exonic splice enhancer mutation that results in a
partly truncated form of the receptor (Δ4-(P)RR) was found in
a family with X-linked mental retardation and epilepsy [83].
No display of cardiovascular or renal abnormalities were
reported. The (P)RR truncation could still bind and activate
renin but was unable to activate Erk1/2.When co-expressed in
PC-12 neuronal cells, Δ4-(P)RR acted as a dominant nega-
tive, by altering localization of wild-type (P)RR and prevent-
ing prorenin-induced Erk1/2 phosphorylation [17].
Genome-wide association studies have identified several
single nucleotide polymorphisms that are associated with
increased cardiovascular risk. In a Japanese cohort, the
intervening sequence 5+169C>T polymorphism was signif-
icantly and independently related to ambulatory blood pres-
sure in men but not in women [35]. The significant higher
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Fig. 2 Functions of the (P)RR in (pro)renin activation and signalling
(left), Wnt signalling (middle), and V-ATPase integrity in autophagic
digestion (right). See text for explanation. Abbreviations used: ACE,
angiotensin-converting enzyme; Ang, angiotensin; Aog, angiotensino-
gen; COX-2, cyclooxygenase-2; EGFR, epidermal growth factor re-
ceptor; Erk1/2, extracellular signal-regulated kinase 1/2; Fz/LRP6,
frizzled/low-density lipoprotein receptor-related protein 6; PAI-1,
plasminogen-activator inhibitor-1; PI3K, phosphoinositide 3-kinase;
PLZF, promyelocytic leukemia zinc finger protein; (P)RR, (pro)renin
receptor; TCF/LEF, T cell factor/lymphocyte enhancer-binding factor;
TGF-β1, transforming growth factor-β1
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ambulatory blood pressure for T-allele carriers was con-
firmed in Caucasian men for the systolic but not diastolic
blood pressure [80]. Renal plasma flow showed no differ-
ence between the two alleles. Also, two polymorphisms, one
in the promoter region and one in an intron of (P)RR, were
significantly associated with hypertension in two vascular
disease populations of CAD (EUROPA) and cerebrovascu-
lar disease (PROGRESS) [8]. In Japanese women, but not
men, the risk of lacunar infarction and left ventricular hy-
pertrophy was significantly and independently associated
with the +1513A>G polymorphism [36]. The risk in GG
women was significantly higher than in women with either
AA or AG genotype, although GGs displayed a lower
plasma renin activity.
Lessons from transgenic models
Efforts to study the role of the (P)RR in cardiovascular
pathology have been hampered by the fact that (P)RR
knockout mice are lethal, and even tissue-specific knock-
outs, as discussed previously, have a life expectancy that is
too short for comprehensive studies [52, 79, 84]. Therefore,
several groups have used transgenic murine models in
which either the (P)RR or its ligand prorenin are overex-
pressed. Binding of rat prorenin to human (P)RR (h(P)RR)
induces Erk1/2 phosphorylation but not prorenin activation
[48], and therefore overexpression of the h(P)RR in rats will
yield an Ang-independent phenotype. These rats are char-
acterized by upregulated expression of the proinflammatory
factor cyclooxygenase 2 (COX-2) in the kidney and the
development of glomerulosclerosis in the absence of hyper-
tension or changes in renal RAS activity [47, 48]. In con-
trast, rats that overexpress the h(P)RR specifically in smooth
muscle cells have elevated blood pressure after 6 months but
normal kidney function [10]. The rise in blood pressure may
be caused by increased plasma aldosterone levels in these
rats. Interestingly, mineralocorticoid receptor blockade has
indeed been proven beneficial in heminephrectomized
(P)RR transgenic rats [70]. In addition, the (P)RR gene
receptor polymorphism associated with increased blood
pressure in Caucasian men is also associated with increased
plasma aldosterone levels [80]. Since prorenin is also se-
creted and released by the adrenal gland, this could mean
that the (P)RR can function as a regulator of intra-adrenal RAS
activity. However, direct effects of prorenin via the (P)RR on
adrenal aldosterone production could not be demonstrated [46].
Although prorenin overexpression was initially reported
to induce renal and cardiac pathology without increasing
blood pressure [102], this could not be confirmed in later
studies by the same group [11] and others [69, 81]. These
later studies did show a rise in blood pressure following
prorenin overexpression. Blood pressure normalized by
concurrent RAS inhibition or expression of an active-site
mutated prorenin [69], indicating that the hypertension was
Ang II-dependent. Indeed, plasma renin decreased after a
200-fold increase in prorenin concentration [81], supporting
intrarenal Ang II formation and a negative feedback effect
on endogenous renin release. As a small percentage (≈2 %)
of plasma prorenin is always in the open form, i.e., capable
of generating Ang I (Fig. 3), a 200-fold increase of plasma
prorenin concentration leads to a substantial increase in Ang
I-generating activity, even without the help of a receptor.
This should be taken into account when considering
prorenin-dependent angiotensin generation.
Active site directed antibody from the IRMA
Prosegment directed antibody from the ELISA
Renin inhibitor 
renin
closed 
prorenin
open inhibited 
prorenin
NH2
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2
ProsegmentNH2
NH
2
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prorenin
+
Fig. 3 Prorenin detection with different assays. Until recently, mea-
suring prorenin immunologically could only be done using a renin-
specific immunoradiometric assay (IRMA). This kit makes use of an
antibody recognizing the active site, and therefore, to allow prorenin
detection, it first has to be converted to renin by cleaving off the
prosegment, e.g., with trypsin. Alternatively, a renin inhibitor can
interfere with the equilibrium that exists between ‘closed’ (inactive)
and ‘open’ (active) prorenin. Normally, >98 % of prorenin is in the
closed conformation. Yet, in the presence of a renin inhibitor, the
equilibrium will shift into the direction of the open conformation [5,
26], i.e., exposing the active site, while the prosegment is still attached.
Indeed, treatment for 48 h at 4 °C with the renin inhibitor aliskiren
(10 μmol/L) [5] fully converts all prorenin molecules to the open
conformation, allowing their detection in a renin-specific assay. This
approach, as well as the proteolytic approach (cleaving off the proseg-
ment), requires renin to be measured before and after treatment in order
to determine the amount of prorenin from the difference between the
two measurements. Recently, a new prorenin specific ELISA has been
developed, making use of an antibody directed against the prosegment
[58], allowing direct prorenin measurement without pretreatment. The
method is fast, and the results are very consistent with those obtained
with the renin IRMA measurements
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Lessons from animal models
Several studies have focused on the (P)RR contribution to
the cardiovascular complications associated with diabetes
mellitus. (P)RR expression is upregulated in the kidneys
from patients [97] and rats [67] with diabetic nephropathy.
To study the involvement of the (P)RR in these models, the
peptidic (P)RR blocker called HRP was developed. HRP
binds to immobilized (P)RR in the nanomolar range and
partly displaces bound renin and prorenin [73, 74]. HRP
infusion normalized renal Ang II levels and prevented the
development of or even reversed existing nephropathy in
diabetic rats [40, 96]. HRP also reduced glomerulosclerosis
in diabetic mice deficient for the AT1a receptor [42] and in
(P)RR transgenic rats [48], indicating that some of the
effects of (P)RR activation in the kidney are independent
of renal Ang II generation. Similarly, retinal inflammation in
diabetic mice was not only reduced by AT1 receptor block-
ade (ARB) in wild-type mice [75] but also by HRP in AT1a
receptor-deficient mice [87]. Also, in hypertensive models,
beneficial effects were found for HRP, for example, in
spontaneously hypertensive rats (SHRs) on a high salt diet,
where it improved kidney and left ventricular function and
decreased left ventricular mass and fibrosis [94]. In stroke-
prone SHRs on a high salt diet, HRP decreased cardiac Ang
II levels and attenuated cardiac fibrosis, without effects on
plasma RAS activity [41]. However, the efficacy of HRP
has been controversial. HRP had no effect on blood pressure
or renal injury in hypertensive Goldblatt rats [4] or double-
transgenic rats that overexpress prorenin and angiotensino-
gen [31]. Furthermore, HRP, at concentrations up to 1μmol/L,
failed to block (pro)renin binding in rat VSMCs over-
expressing human (P)RR [4], or Erk1/2 phosphorylation
in human VSMCs [31] and U937 monocytes [30] ex-
posed to prorenin. Moreover, even at 100 μmol/L, HRP
blocked renin and prorenin binding only partly [73].
Indeed, Leckie et al. [59] were unable to find a specific
binding place for HRP on HUVECs.
The (P)RR and RAS inhibition
Renin secretion is under tight control of Ang II levels
through a negative feedback loop, and therefore RAS block-
ade causes a reactive rise in plasma renin and, to a lesser
extent, plasma prorenin concentrations. Direct renin inhibi-
tion appeared to increase the renin concentration even more
than ACE inhibition (ACEi) or ARB, due to the detection of
prorenin as renin [57] (Fig. 3) and decreased renin/prorenin
clearance [5]. Hence, RAS inhibition (and in particular renin
inhibition) could in theory have adverse effects through
activation of the (P)RR. It has been suggested [28] that this
may explain the increased risk of cardiovascular death in
hemodialysis patients that undergo dual therapy with ACEi
and ARB as compared with a single RAS blocker [12].
However, this is as yet speculative and not corroborated
by other studies so far [21]. In cells, (pro)renin stimulation
of PLZF downregulates the expression of the (P)RR gene
through a short negative-feedback loop [89], which is un-
opposed by the renin inhibitor aliskiren [29, 31, 90]. Could
decreased (P)RR expression explain the absence of (P)RR-
dependent effects during RAS inhibition? In diabetic TG
(mRen-2) rats, aliskiren reduced (P)RR expression in glo-
meruli, tubules, and cortical vessels [29]. However, the
(P)RR was upregulated in the clipped kidney of Goldblatt
hypertensive rats treated with a vasopeptidase inhibitor,
when both plasma (pro)renin and renal renin are strongly
increased [54]. In addition, other factors than PLZF, for
example, COX-2 in diabetes [13, 39], can regulate (P)RR
expression, so, clearly, (P)RR expression is the result of
more factors than just prorenin.
Is there an additional benefit of add-on therapy, i.e.,
(P)RR inhibition on top of ACEi or ARB? In an experimen-
tal model, using cultured glomeruli from rats with anti-Thy-
1-induced glomerulonephritis, addition of (P)RR siRNA to
an already maximal dose of the ACE inhibitor enalaprilate
further decreased fibrotic factor production compared with
single therapy [108]. However, in SHR rats with add-on
therapy of HRP different results were obtained. While
HRP combined with an ACEi decreased heart weight and
urinary protein excretion more than with ACEi alone [92], it
reversed the beneficial effects of aliskiren on cardiac hyper-
trophy, blood pressure, and coronary circulation [101].
Again, the results with HRP have to be considered with
care and raise the necessity for other (P)RR blockers that
prove their efficacy and specificity in both in vitro and in
vivo models.
The (P)RR: a physiological (pro)renin receptor?
If anything has become clear from the in vivo models, it is
that, in spite of the promise, the results have been under-
whelming. Models with prorenin overexpression were
found to display an Ang II-dependent phenotype [11, 69,
81], which can be explained, at least in part, by the well-
known fact that a small part of prorenin is present in its open
active form in plasma. Does (pro)renin–(P)RR interaction
ever occur in vivo? The dissociation constants for renin and
prorenin range between 1 and 20 nM, depending on the use
of membrane fractions of (P)RR overexpressing cells [4,
76], or immobilized receptors [72, 74]. With a few excep-
tions, most in vitro experiments that show (P)RR-dependent
signalling use (pro)renin concentrations in this range. How-
ever, plasma renin and prorenin concentrations are in the
picomolar range (≈0.5 and 5 pmol/L, respectively) [24].
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Plasma renin concentration can be increased up to 100-fold
by, among others, Bartter’s syndrome, renal artery stenosis
or RAS inhibition, and prorenin concentration are increased
by maximally five- to tenfold in pregnancy and in patients
with diabetes [88]. Even the excessive prorenin levels pres-
ent in transgenic models are still an order of magnitude
below those applied in vitro. A recent detailed study by
Batenburg et al. [6] investigated the effect of different con-
centrations of human prorenin and renin in VSMCs that
overexpress the human (P)RR. In this model, 4 nmol/L
prorenin induced DNA synthesis and PAI-1 production only
in the presence of angiotensinogen, whereas 20 nmol/L
prorenin was required to achieve angiotensin-independent
phosphorylation of Erk1/2, which is respectively ~800- and
~4,000-fold higher than normal. Renin induced DNA syn-
thesis, Erk1/2 phosphorylation, and PAI-1 release at 1 nmol/L
(~2,000-fold higher than normal) both in human (P)RR
expressing and wild-type cells. As plasma concentrations
reflect the extracellular fluid concentration, the prorenin levels
in prorenin transgenic animals might thus, at most, result in
some modest (P)RR-dependent angiotensin generation, and
direct activation of the (P)RR by these levels still seems
impossible.
From this point of view, (pro)renin–(P)RR interaction in
wild-type animals (including humans under pathological con-
ditions) seems only possible in (pro)renin synthesizing organs
like the kidney. (P)RR expression is upregulated, and (pro)
renin is secreted in the collecting duct of the kidney under
diabetic conditions [49, 67]. In contrast to most other cell
types, the (P)RR is abundantly present at the plasma mem-
brane of the intercalated cells of the collecting duct [1]. Since
Erk1/2 phosphorylation is already evident at low picomolar
concentrations in MDCK cells [1], as well as mesangial cells
[37], it is possible that a sufficient number of receptors are
occupied in the collecting duct to elicit (P)RR-dependent
signalling. The ovaries secrete prorenin as well, and, although
the prorenin concentrations in follicular fluid are on average
only ≈10 times higher than in plasma, it seems to affect
follicular development and oocyte maturation, as the follicular
prorenin concentration correlated inversely with follicular
atresia [44]. Also, prorenin, secreted from the chorion leave,
in the gestational sac during the first trimester can reach up to
1 μg/mL [45], which could be high enough for (P)RR stimu-
lation and has been suggested to play a role in fetal and
embryonic development [45].
(Pro)renin-independent functions for the (P)RR in Wnt
signalling
The interaction between the (P)RR and the V-ATPase is not
only important for V-ATPase integrity but for signal transduc-
tion as well. The (P)RR gene was identified in human
embryonic kidney cells in an siRNA library screen designed
to find previously unknown components of the canonical
Wnt/β-catenin signalling pathway [19]. The canonical Wnt/
β-catenin signalling pathway is important for embryonic de-
velopment and tissue homeostasis and has been implicated in
certain pathologies, such as cancer and diabetes. Binding of
Wnt to frizzled/low-density lipoprotein receptor-related pro-
tein 6 (Fz/LRP6) complex results in stabilization ofβ-catenin,
which then translocates to the nucleus where it complexes
with the T cell factor/lymphocyte enhancer binding factor
(TCF/LEF) to induce the expression of Wnt target genes
[15, 66]. Wnt/β-catenin signalling requires the internalization
of the Fz/LRP6 complex and subsequent acidification of the
signalling endosomes by V-ATPases. Acidification of the
endosomes requires the presence of the (P)RR, which acts as
a physical adaptor between the Fz/LRP6 complex and the V-
ATPase [19]. In the Wnt/planar cell polarity (Wnt/PCP) path-
way, which regulates the polarization of cells in the plane of
tissues, the (P)RR also binds and targets Fz-receptors and is
required for gastrulation in Xenopus and orientation of
wing hairs and notum bristles in Drosophila [9, 34].
Importantly, since (pro)renin is not present in early
Xenopus embryos [19] and (pro)renin has not been
identified in Drosophila, these functions of the (P)RR
are independent from (pro)renin.
Can some of the phenotypes associated with the (P)RR be
explained by changes inWnt- signalling? In diabetic nephrop-
athy, COX-2 exacerbates the disease by upregulating (P)RR
expression in podocytes, which contributes to albuminuria,
foot-process effacement, and mesangial matrix expression
[13]. Combined with the COX-2 upregulation in (P)RR trans-
genic mice [47], this suggests a link between the (P)RR,
COX-2, and renal injury. However, COX-2 is also a target gene
for Wnt/β-catenin signalling [78]. Furthermore, Wnt/β-catenin
signalling is increased in podocytes and glomeruli of patients
and mouse models with diabetic kidney disease [50]. A bal-
anced amount of Wnt/β-catenin signalling seems required for
proper kidney function, as both overexpression and deletion of
β-catenin in podocytes leads to podocyte dysfunction and
susceptibility to diabetic kidney disease [50]. Importantly, renal
Wnt/β-catenin signalling acts downstream of TGF-β1 to
induce expression of profibrotic markers, including PAI-1, that
contributes to renal fibrosis, podocyte injury, and proteinuria
[33, 104]. So it appears that some of the signalling molecules
involved in (pro)renin signalling in vitro are also important
players in Wnt/β-catenin signalling in renal pathology. Hence,
the effects of (P)RR overexpression may also be due to over-
activation of the Wnt/β-catenin pathway, independent from
(pro)renin. In addition, since Δ4-(P)RR not only inhibits
(pro)renin signalling in neurons but also neural growth factor
signalling [17], the possibility that the (P)RR is in-
volved in other signalling pathways as well cannot be
excluded.
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Conclusions
After 10 years of research, the (P)RR still has a case to make
to deserve its name. In spite of the in vitro findings, the
evidence in in vivo models argues against a (pro)renin-
dependent function for the (P)RR. Models that have high
plasma levels of (pro)renin have a phenotype that is entirely
dependent on Ang II formation, which can possibly even be
explained without the need for the (P)RR. The (pro)renin
levels in these models are an order of magnitude higher than
in the most severe pathological models but still an order of
magnitude lower than the concentrations required in virtu-
ally all cell-based models, and thus a (pro)renin–(P)RR
interaction outside (pro)renin-synthesizing cells appears im-
possible. Even though beneficial effects for the putative
(P)RR blocker HRP have been reported, this has been con-
tradicted by others, and the efficacy in specificity of HRP is
questionable, raising the need for more effective and selec-
tive (P)RR blockers. Overexpression of the (P)RR yields
conflicting results and raises the question whether the ob-
served effects depend on (pro)renin binding. Deletion of the
(P)RR gene, even in individual tissues, results in a lethal
phenotype. Thus, a balanced amount of (P)RR expression
seems vital for normal tissue behavior. The same is true for
the Wnt/β-catenin pathway, where too much or too little
activity interferes with tissue homeostasis. Thus, the ques-
tion arises if not (pro)renin binding but altered Wnt/β-cat-
enin signalling is responsible for many, if not most, of the
phenotypes of models in which (P)RR overexpression is
altered. Clearly, compelling in vivo data are required to
address this question. In addition, the (P)RR could have a
more universal function as an adaptor protein, therefore
another challenge will be to determine whether the (P)RR
mediates signal output of other pathways than those initiated
by Wnt molecules as well. Consequently, the (P)RR may not
be a suitable drug target in cardiovascular and renal dis-
eases. As a role of a (pro)renin–(P)RR interaction in patho-
physiology still needs to be proven and the receptor appears
an essential component of the V-ATPase, interference with
(P)RR function may even be detrimental.
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